IPBiz: Natco Pharma challenges Gilead patent on Tamiflu

Friday, February 11, 2011

Natco Pharma challenges Gilead patent on Tamiflu

MoneyControl writes: Natco Pharma has challenged a patent on Tamiflu (Oseltamivir Phosphate)—a drug used in the treatment of bird and swine-flu infections, reports the PTI.

See previous IPBiz posts, including

More on Tamiflu and Gilead's US 5,763,483

keywords: Hatch-Waxman, ANDA

0 Comments:

Post a Comment

<< Home

Name: Lawrence B. Ebert

I'm a patent lawyer located in central New Jersey. I have a J.D. from the University of Chicago and a Ph.D. from Stanford University, where I studied graphite intercalation compounds at the Center for Materials Research. I worked at Exxon Corporate Research in areas ranging from engine deposits through coal and petroleum to fullerenes. An article that I wrote in The Trademark Reporter, 1994, 84, 379-407 on color trademarks was cited by Supreme Court in Qualitex v. Jacobson, 514 US 159 (1995) and the methodology was adopted in the Capri case in N.D. Ill. An article that I wrote on DNA profiling was cited by the Colorado Supreme Court (Shreck case) and a Florida appellate court (Brim case). I was interviewed by NHK-TV about the Jan-Hendrik Schon affair. I am developing ipABC, an entity that combines rigorous IP analytics with study of business models, to optimize utilization of intellectual property. I can be reached at C8AsF5 at yahoo.com.

View my complete profile

IPBiz

Friday, February 11, 2011

Natco Pharma challenges Gilead patent on Tamiflu

0 Comments:

About Me

Previous Posts